Home/Pipeline/Nanrilkefusp alfa (SOT201)

Nanrilkefusp alfa (SOT201)

Solid Tumors

Phase 1/2Active

Key Facts

Indication

Solid Tumors

Phase

Phase 1/2

Status

Active

Company

SOTIO Biotech

About SOTIO Biotech

SOTIO Biotech is a private, clinical-stage biotech company headquartered in Prague, Czech Republic, with a strategic presence in the US and Europe. It is developing a diversified pipeline of immunotherapies, including the IL-15 superagonist nanrilkefusp alfa (SOT201) and several ADC candidates (SOT106, SOT109) targeting solid tumors. Backed by the PPF Group, the company leverages proprietary and partnered technology platforms to translate compelling science into patient benefit, with a business model centered on therapeutic development.

View full company profile

Therapeutic Areas

Oncology Solid Tumors

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed